
GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead. The UK firm saw 4% …
GlaxoSmithKline is set to receive a green light to use its anti-clotting drug Arixtra to prevent spontaneous superficial-vein thrombosis (SVT). …
The US Food and Drug Administration has taken the advice of its advisors and given its backing to resume the …
FDA advisors have recommended two rotavirus vaccines licensed in the US should continue to be used, despite contamination with a …